Helen Thackray
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Helen Thackray
Helen Thackray was last confirmed as Board Member at Biocryst Pharmaceuticals Inc (BCRX) in a filing dated April 13, 2021. The proxy statement of Biocryst Pharmaceuticals Inc reports total compensation of $4,339,624 for Helen Thackray in fiscal 2025, including a base salary of $425,999. Disclosed compensation is on record for 5 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2019-01-01–2021-04-13
Last confirmed by a filing; no departure on record
-
Biocryst Pharmaceuticals Inc (BCRX)
Proxy statement
Start not stated–2025-09-01
-
Crescent Biopharma, Inc. (CBIO)
Proxy statement
Start not stated–2021-03-19
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biocryst Pharmaceuticals Inc (BCRX) | Former Chief R&D Officer | $425,999 | $4,339,624 |
| 2024 | Biocryst Pharmaceuticals Inc (BCRX) | Chief R&D Officer | $599,423 | $3,568,850 |
| 2023 | Biocryst Pharmaceuticals Inc (BCRX) | Chief R&D Officer | $576,368 | $2,393,933 |
| 2022 | Biocryst Pharmaceuticals Inc (BCRX) | Chief R&D Officer | $554,200 | $3,497,932 |
| 2021 | Biocryst Pharmaceuticals Inc (BCRX) | Chief R&D Officer | $425,125 | $6,881,396 |
Recent activity
No call appearances or filed executive changes recorded yet.